When.com Web Search

  1. Ads

    related to: what is sickle cell disease

Search results

  1. Results From The WOW.Com Content Network
  2. Pfizer withdraws sickle cell disease treatment on risk of ...

    www.aol.com/news/pfizer-withdraws-sickle-cell...

    Pfizer bought Oxbryta, also known as voxelotor, as part of its $5.4 billion buyout of Global Blood Therapeutics in 2022. Pfizer is also discontinuing all studies and access programs related to the ...

  3. Pfizer's Oxbryta exit may hasten trials of rival experimental ...

    www.aol.com/news/pfizers-oxbryta-exit-may-hasten...

    Sickle cell disease affects an estimated 100,000 people in the U.S., most of whom are Black. The withdrawal is the latest headwind for Pfizer and its CEO Albert Bourla. Investors have punished the ...

  4. New prescription drug price hikes hit Black patients hard - AOL

    www.aol.com/news/prescription-drug-price-hikes...

    One example she cites is the health care industry’s handling of sickle cell anemia, which 1 in 13 Black babies in the U.S. are born with, according to the Centers for Disease Control and Prevention.

  5. Malaria - Wikipedia

    en.wikipedia.org/wiki/Malaria

    Sickle cell trait causes a change in the haemoglobin molecule in the blood. Normally, red blood cells have a very flexible, biconcave shape that allows them to move through narrow capillaries ; however, when the modified haemoglobin S molecules are exposed to low amounts of oxygen, or crowd together due to dehydration, they can stick together ...

  6. Pulmonary hypertension - Wikipedia

    en.wikipedia.org/wiki/Pulmonary_hypertension

    However, in systemic lupus erythematosus it is 4 to 14%, [106] and in sickle cell disease, it ranges from 20 to 40%. [107] Up to 4% of people who develop a pulmonary embolism go on to develop chronic thromboembolic disease including pulmonary hypertension. [ 40 ]

  7. CRISPR gene editing - Wikipedia

    en.wikipedia.org/wiki/CRISPR_gene_editing

    In 2023, the first drug making use of CRISPR gene editing, Casgevy, was approved for use in the United Kingdom to cure sickle-cell disease and beta thalassemia. [13] [14] Casgevy was approved for use in the United States on December 8, 2023, by the Food and Drug Administration. [15]